{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:23:25Z","timestamp":1791487405396,"version":"4.3.4"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) is a promising HIV prevention tool for people who inject drugs (PWID), who face elevated HIV risk and barriers to care. While acceptable to PWID, CAB-LA implementation in low-barrier syringe services programs (SSPs) has not been examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From August 2023 to July 2025, we conducted semistructured interviews with 12 SSP staff involved in CAB-LA delivery. Interviews were transcribed and analyzed using thematic analysis guided by the Consolidated Framework for Implementation Research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Facilitators included CAB-LA's relative advantage over oral PrEP, external technical support, 340B pharmacy revenue, alignment with SSP mission and workflows, motivated staff, and financial incentives. Barriers included lack of FDA approval for PWID, complex logistics, performance pressures, infrastructure constraints, competing priorities, staff workload, and client outreach and engagement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating CAB-LA into SSPs is promising, but successful implementation requires targeted strategies, including additional resources, workflow adaptations, and enhanced outreach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23259582261420655","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:39:46Z","timestamp":1770831586000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-618X","authenticated-orcid":false,"given":"Marina","family":"Plesons","sequence":"first","affiliation":[{"name":"University of Miami Miller School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2010-8008","authenticated-orcid":false,"given":"Elana","family":"Forman","sequence":"additional","affiliation":[{"name":"Drexel University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin C","family":"McDowell","sequence":"additional","affiliation":[{"name":"Drexel University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Krakower","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center"},{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Rivet","family":"Amico","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison K","family":"Groves","sequence":"additional","affiliation":[{"name":"Drexel University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Roth","sequence":"additional","affiliation":[{"name":"Drexel University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S","family":"Bartholomew","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1343"},{"key":"e_1_3_3_3_2","volume-title":"HIV surveillance report, 2021","author":"Centers for Disease Control and Prevention","year":"2023","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report, 2021. Centers for Disease Control and Prevention; 2023."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60832-X"},{"key":"e_1_3_3_5_2","volume-title":"HIV infection risk, prevention, and testing behaviors among persons who inject drugs\u2014National HIV behavioral surveillance: Injection drug use, 23 U.S. cities, 2018","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. HIV infection risk, prevention, and testing behaviors among persons who inject drugs\u2014National HIV behavioral surveillance: Injection drug use, 23 U.S. cities, 2018. Centers for Disease Control and Prevention; 2020."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2021.2012688"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04308-z"},{"key":"e_1_3_3_8_2","volume-title":"FDA approves first injectable treatment for HIV pre-exposure prevention silver springs","author":"US Food and Drug Administration","year":"2021","unstructured":"US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention silver springs. US Food and Drug Administration; 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43058-024-00637-1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac716"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp4711"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21493"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26107"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-025-04833-5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02767-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2022.0068"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587356"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-021-00556-z"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587352"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04285-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07572-3"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2020.0164"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108058"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04598-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2024.2390067"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2019.31.4.363"},{"key":"e_1_3_3_29_2","unstructured":"Patel SV Wenger LD Pindyck T et al. Program and operational characteristics of syringe services programs\u2014Survey data covering the United States its territories and tribal nations. 2022. 2024."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1037\/13620-000"},{"key":"e_1_3_3_33_2","unstructured":"Roth A. Trauma intervention to optimize PrEP among women who inject drugs (TIARAS). Clinical Trials Identifier: NCT05192434. ClinicalTrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05192434."},{"key":"e_1_3_3_34_2","volume-title":"The status neutral approach: A whole-person approach to ending the HIV epidemic in the US","author":"Daskalakis D","unstructured":"Daskalakis D. The status neutral approach: A whole-person approach to ending the HIV epidemic in the US. Centers for Disease Control and Prevention. https:\/\/www.naccho.org\/uploads\/body-images\/NACCHO-Status-Neutral-Approach-Daskalakis.pdf"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261420655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582261420655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261420655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:54Z","timestamp":1777503054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582261420655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"alternative-id":["10.1177\/23259582261420655"],"URL":"https:\/\/doi.org\/10.1177\/23259582261420655","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"23259582261420655"}}